---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-076136"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:49:16.904369+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Immunome merges with Morphimmune; Siegall new CEO; $125M PIPE at $5.75/share

## Summary
- Morphimmune stockholders to own ~45% of combined company; Immunome stockholders ~55% on fully diluted basis.
- Clay Siegall to become Chairman and CEO; board to include 2 from Morphimmune, 1 from Immunome, 4 independents.
- PIPE financing of ~$125M at $5.75/share (or $5.91 for affiliates) from Enavate, EcoR1, Redmile.
- Siegall employment agreement: $650K base, 50% bonus target, option for 2.14M shares at $5.91.
- Closing conditions include S-4 effectiveness, Nasdaq listing, PIPE proceeds of $125M.

## SEC filing metadata
- accession: 0001104659-23-076136
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923076136/0001104659-23-076136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923076136/tm2320045d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-076136
- JSON: https://secwatch.observer/filing/0001104659-23-076136.json
- Plain text: https://secwatch.observer/filing/0001104659-23-076136.txt

## Key facts
- Material Agreements
  Immunome Inc. entered into Agreement and Plan of Merger and Reorganization with Morphimmune Inc. (effective 2023-06-29).
  - Action: entry
  - Agreement: merger
  - Counterparty: Morphimmune Inc.
  - Effective: 2023-06-29
  source text: On June 29, 2023, Immunome, Inc., a Delaware corporation (“Immunome”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Morphimmune Inc., a Delaware corporation (“Morphimmune”), a biotechnology company focused on developing targeted oncology therapeutics, and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Immunome (“Merger Sub”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923076136/0001104659-23-076136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.